Drug Profile
Research programme: melanocyte stimulating hormone analogues - Melacure Therapeutics
Alternative Names: Alpha-melanocyte stimulating hormone analogues - Melacure Therapeutics; Alpha-MSH analogues research programme - Melacure Therapeutics; Melanocyte stimulating hormone analogues research programme - Melacure Therapeutics; MS05; MS09; MSH analogues research programme - Melacure Therapeutics; Research programme: alpha-melanocyte stimulating hormone analogues - Melacure Therapeutics; Research programme: alpha-MSH analogues - Melacure Therapeutics; Research programme: MSH analogues - Melacure TherapeuticsLatest Information Update: 18 Aug 2003
Price :
$50
*
At a glance
- Originator Melacure Therapeutics (CEASED); University of Muenster; Uppsala University
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 18 Aug 2003 Discontinued - Preclinical for Inflammation in Sweden (unspecified route)
- 07 Nov 2002 No development reported - Preclinical for Inflammation in Sweden (unspecified route)
- 26 Jul 2000 Preclinical development for Inflammation in Sweden (Unknown route)